3.6M Share Offering at $2.75/Share; To Uplist to N
Post# of 223
Posted On: 06/25/2015 10:55:21 AM
3.6M Share Offering at $2.75/Share; To Uplist to NYSE MK
June 25, 2015 7:08 AM
BioPharmX Corporation (NYSE: BPMX) announced the pricing of a public offering of 3,636,364 shares of common stock at a price to the public of $2.75 per share for an aggregate offering amount of $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company. In addition, BioPharmX has granted the underwriters a 30-day option to purchase up to 545,454 additional shares of common stock at the public offering price. In conjunction with the pricing of the offering, the company is simultaneously uplisting to the NYSE MKT today, and begins trading under the ticker symbol "BPMX." All shares of common stock to be sold in the offering are being offered by BioPharmX. The offering is expected to close on or about June 30, 2015, subject to customary closing conditions.
In addition, Korea Investment Partners Overseas Expansion Platform Fund, an existing stockholder, has agreed to purchase 1,081,081 shares of common stock from BioPharmX in a private placement upon the uplisting of the company's common stock to the NYSE MKT. This private placement is anticipated to close within 15 business days of the uplisting of the company's common stock to the NYSE MKT.
CRT Capital Group LLC is acting as sole book-running manager for the offering. Feltl and Company, Inc. and Newbridge Securities Corporation are acting as co-managers for the offering.
June 25, 2015 7:08 AM
BioPharmX Corporation (NYSE: BPMX) announced the pricing of a public offering of 3,636,364 shares of common stock at a price to the public of $2.75 per share for an aggregate offering amount of $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company. In addition, BioPharmX has granted the underwriters a 30-day option to purchase up to 545,454 additional shares of common stock at the public offering price. In conjunction with the pricing of the offering, the company is simultaneously uplisting to the NYSE MKT today, and begins trading under the ticker symbol "BPMX." All shares of common stock to be sold in the offering are being offered by BioPharmX. The offering is expected to close on or about June 30, 2015, subject to customary closing conditions.
In addition, Korea Investment Partners Overseas Expansion Platform Fund, an existing stockholder, has agreed to purchase 1,081,081 shares of common stock from BioPharmX in a private placement upon the uplisting of the company's common stock to the NYSE MKT. This private placement is anticipated to close within 15 business days of the uplisting of the company's common stock to the NYSE MKT.
CRT Capital Group LLC is acting as sole book-running manager for the offering. Feltl and Company, Inc. and Newbridge Securities Corporation are acting as co-managers for the offering.
(0)
(0)